The α 1 -adrenergic receptors (α 1 -ARs), which belong to a G protein-coupled receptor family, consist of three highly homologous subtypes known as α 1A -ARs, α 1B -ARs, and α 1D -ARs. Our previous findings suggested that α 1A -ARs are an important target for imipramine and electroconvulsive therapy. The current study sought to evaluate whether S-(+ )-niguldipine and B8805-033, two selective antagonists of α 1A -ARs, can evoke antidepressant-like effects in the forced swim test in rats. Both compounds were administered at three time points (24, 5, and 1 h before testing), and the effects of three doses (2, 5, and 10 mg/kg) of each compound were investigated. S-(+ )-Niguldipine produced no antidepressant-like effects other than a 14% reduction in immobility time at the highest dose. Although B8805-033 at a dose of 2 mg/kg did not influence the rats' behavior, higher B8805-033 doses (5 and 10 mg/kg) produced significant reductions in immobility time (approximately 42 and 44% vs. controls, respectively; P < 0.01). However, this effect was abolished by the concomitant administration of WAY100135, a serotonin receptor antagonist, suggesting that the observed antidepressant-like effects of B8805-033 are unrelated to α 1A -ARs. Nevertheless, given the current dearth of selective α 1A -AR agonists, the question of whether this particular subtype could be involved in antidepressant therapy mechanisms remains unresolved. Behavioural Pharmacology 27:397-401
Introduction α 1 -Adrenergic receptors (α 1 -ARs) are G protein-coupled receptors on the cell membrane that activate inositol phosphate turnover in response to the physiological agonist noradrenaline. On the basis of current knowledge, three main subtypes of α 1 -ARs can be distinguished: α 1A -ARs, α 1B -ARs, and α 1D -ARs (Nalepa et al., 2013) . Our previous findings have indicated that the α 1A -AR subtype appears to be an important target for imipramine (IMI) and electroconvulsive therapy (Nalepa et al., 2002) . We have found that, of the two subtypes of cerebral α 1 -ARs that have been investigated, the α 1A -AR underwent adaptive changes after repeated administration of electroconvulsive shock (ECS) and IMI. Both treatments elevated the α 1A -AR mRNA and the expression of receptor protein, whereas the α 1B -AR remained unchanged (Nalepa et al., 2002) . This observation was supported by a recent study in which DSP-4-induced lesion of the noradrenergic system attenuated the increase of α 1A -AR mRNA induced by chronic IMI treatment, and abolished the effect of ECS, in the prefrontal cortex of the rat brain (Kreiner et al., 2011) . The latter effect was also confirmed at the protein level as reflected by changes observed in the density of α 1 -AR subtypes (Kreiner et al., 2011) . However, it was unclear whether the observed changes in α 1A -AR expression could have been directly responsible for the antidepressant effects of the treatments that were examined.
The aim of the current study was to evaluate the possible antidepressant-like effects of compounds that selectively act through α 1A -ARs in the forced swim test (FST). Owing to the current dearth of selective α 1A -AR agonists (Docherty, 2010; Nalepa et al., 2013) , antagonists were the only compounds of choice for this investigation. Two α 1A -AR antagonists, S-(+ )-niguldipine and B8805-033 3,5-trimethyl-6-[[3-[4-((2,3- dihydro-2-hydroxymethyl)-1,4-benzodioxin-5-yl)-1-piperazinyl-propylamino]-2,4(1H,3H)-pyrimi-dinedione)], were selected for our experiments because these compounds exhibit high levels of discrimination between α 1A -AR and other α 1 -AR subtypes (Boer et al., 1989; Eltze et al., 2001a; Wang et al., 2001) .
Therefore, the aim of this study was to investigate in vivo the working hypothesis that α 1A -AR can have a pivotal role in mediating the antidepressant-like effects by examining compounds that selectively act through this receptor.
Methods

Subjects
Experiments were performed on male Wistar rats (230-250 g) kept under standard animal housing conditions, randomly divided into experimental groups (n = 8-12). All experimental protocols were approved by the Local Bioethics Commission for Animal Experiments at the Institute of Pharmacology of the Polish Academy of Sciences in Kraków.
Experimental procedure
The animals were individually subjected to the classic FST procedure (Porsolt et al., 1977) . Briefly, before testing, rats were placed in 50 × 30-cm tubes half filled with water (at 25°C) for 15 min, then removed from the tubes, dried, and placed into a new cage. The FST was performed 24 h later using the same procedure, although with only 5 min of swimming. Total immobility time was manually scored blind to drug treatment. IMI was used as a positive control in all experiments. In addition, B8805-033, at the same doses as in the FST, was automatically evaluated for spontaneous locomotor activity in an open field test (OFT) by use of the Opto-Varimex AutoTrack System (Columbus Instruments, Columbus, Ohio, USA) as previously described (Nalepa et al., 2007) .
Drugs administration
S-(+ )-Niguldipine (Altana Pharma AG, Konstanz, Germany) and B8805-033 (Altana Pharma AG) were dissolved in 1% Tween 80 and administered at doses of 2, 5, and 10 mg/kg. WAY100135 (own synthesis) and IMI (Pliva, Kraków, Poland) were dissolved in distilled water and administered at doses of 0.1 and 0.3 mg/kg for WAY100135 and at 20 mg/kg for IMI. All compounds were injected intraperitoneally three times (at 24, 5, and 1 h before testing). When administered concomitantly, WAY100135 was injected 15 min before S-(+ )-niguldipine or B8805-033 injections. Control rats received 1% Tween 80.
Statistical analysis
Statistica 8.0 software (StatSoft, Tulsa, Oklahoma, USA) was used for statistical analysis of the results. The data were evaluated by one-way analysis of variance (ANOVA) (dose-dependent effects for a particular compound) or by two-way ANOVA (concomitant administration with WAY100135, with the following four groups analyzed together: VEH + VEH, WAY + VEH, VEH + B88, and WAY + B88), followed by LSD tests. The data are expressed as the means SEM for 8-12 rats. P values less than 0.05 were regarded as significant.
Results
At lower doses (2 and 5 mg/kg), S-(+ )-niguldipine did not change immobility time relative to control animals. The highest dose (10 mg/kg) slightly shortened the immobility time (a decrease of ∼ 14% vs. control; P < 0.05) ( Fig. 1a ). At 2 mg/kg, B8805-033 did not influence the rats' behavior in the FST; however, higher doses (5 and 10 mg/kg) produced significant decreases in immobility times (approximately 42 and 44% vs. controls, respectively; P < 0.01) ( Fig. 1b) . One-way ANOVA revealed significant effect of S-(+ )-niguldipine and B8805-033 treatment (F = 14.73, P < 0.001; F = 22.69, P < 0.001; respectively).
To ensure that the behavior observed in the FST was clearly related to the antidepressant-like effect of B8805-033 and not secondary to a psychostimulant response of that compound, spontaneous locomotor activity in the OFT was assessed. No statistically significant differences between B8805-033 (2, 5, 10 mg/kg) and control rats were observed at any dose or time interval evaluated (Fig. 1c ).
Because B8805-033 has an affinity to serotonin 5-HT 1A receptors (Eltze et al., 2001a) that may have affected the experimental results, the B8805-033 experiments were repeated under conditions involving the pharmacological blockade of 5-HT 1A by WAY100135, a nonselective serotonin antagonist without antidepressant properties. Tests with the concomitant administration of WAY100135 and B805-033 revealed that, depending on the injected dose, WAY100135 attenuated (at 0.1 mg/kg; ∼ 20% decrease; P < 0.05) or abolished (at 0.3 mg/kg) the previously observed effects of B8805-033 administration. The two-way ANOVA revealed the statistically significant interaction between WAY100135 x B8805-033 at F(1,44) = 10.15, P = 0.0026 and F(1,42) = 8.24, P = 0.0064, for WAY 0.1 mg/kg and WAY 0.3 mg/kg, respectively. The administration of WAY100135 alone (0.1 mg/kg) did not alter animals' immobility times relative to controls (Fig. 2) .
Treatment with IMI (a classic antidepressant drug well known for its positive effects in the FST) produced a decrease in immobility time (of 45-61%) relative to control animals in all sets of experiments, thereby validating the results obtained after administration of the investigated compounds (Figs 1 and 2 ).
Discussion
Our previous experiments suggested that the α 1A -AR subtype can be regarded as an important therapeutic target for antidepressant treatment: studies on the level of mRNA encoding for α 1A -AR and α 1B -AR subtypes and receptor protein expression revealed that in the prefrontal cortex only α 1A -AR was involved in the response to chronic administration of the noradrenaline-related antidepressants, IMI and ECS (Nalepa et al., 2002; Kreiner et al., 2011) . Our observations were indirectly confirmed by the study of Doze et al. (2009) in transgenic mice engineered to express a constitutively active mutant form of α 1A -AR or α 1B -AR, which demonstrated that these two receptors differentially modulate antidepressant-like behavior: in particular, only overexpression of α 1A -AR signaling promoted antidepressantlike behavior in the tail suspension test and FST, and, on the contrary, α 1B -AR mutant mice were characterized by depressive-like behavior (Doze et al., 2009 ). These findings prompted us to investigate whether α 1A -ARs can play a pivotal role in the antidepressant-like response evoked by selective ligand administration. Because there are currently no selective agonists that differentiate among α 1 -AR subtypes (Docherty, 2010; Nalepa et al., 2013) , we focused our investigation on two α 1A -AR antagonists, S-(+ )-niguldipine and B8805-033, and evaluated these compounds' efficacy as antidepressants in rats in the FST. There exist clinically effective antidepressants that can act as α 1 -AR antagonists (e.g. IMI and mianserin; Vetulani, 1991, 1994) , and exhibit antidepressant-like potential in the FST and/or tail suspension test (Cryan et al., 2005; Petit-Demouliere et al., 2005 ).
An important reason why these two compounds were chosen was their prominent selectivity for α 1A -ARs relative to the other α 1 -AR subtypes, α 1B -ARs and α 1D -ARs. This selectivity was confirmed by radioligand binding studies indicating that S-(+ )-niguldipine and B8805-033 have 340-630-fold and 150-1200-fold greater affinity, The influence of S-(+ )-niguldipine (a) and B8805-033 (b) treatment on antidepressant-like behavior in the forced swim test in rats. (c) Open field test: distance traveled across 10-min time intervals in the open field. VEH, vehicle, control group; IMI, imipramine (3 × at 20 mg/kg); NIG, niguldipine (3 × at 2, 5, or 10 mg/kg); B88, B8805-033 (3 × at 2, 5, or 10 mg/kg). *P < 0.05 versus control group; **P < 0.01 versus control group; n = 12.
Antidepressant-like effects and α 1A -AR antagonists Kreiner et al. 399 respectively, for α 1A -ARs than for other α 1 -ARs (Boer et al., 1989; Wetzel et al., 1995; Eltze et al., 2001a) .
Notably, there exist other compounds, such as tamsulosin, silodosin (KMD-3213), Rec 15/2739, Ro70-0004, and RS-100329, that discriminate between α 1A -AR and α 1B -AR subtypes with even greater selectivity. However, these were not considered for this study because they exhibit lower or indeterminate selectivity in differentiating between α 1A -ARs and α 1D -ARs (Michel and Insel, 1994; Murata et al., 1999; Williams et al., 1999; Kuo et al., 2000; Eltze et al., 2001b; Kobayashi et al., 2009) . Moreover, another attractive characteristic of S-(+ )niguldipine is its documented potential to cross the blood-brain barrier (Borowicz et al., 2002) ; it was unclear whether other candidate compounds possessed this capability. Unfortunately, both of the tested compounds are not solely selective α 1A -AR antagonists. S-(+ )-Niguldipine (a dihydropyridine derivative) is also a partial calcium channel blocker (Boer et al., 1989) , whereas B8805-033 has been reported to possess an affinity to 5-HT 1A receptors (Eltze et al., 2001a) .
We observed moderate antidepressant-like effects at the highest tested dose of S-(+ )-niguldipine. Although the observed 14% decline in immobility time was statistically significant, this decrease appears to be overly mild for an unbiased antidepressant-like effect, and the significance of this decrease may simply reflect the relatively high number of animals screened in this experiment. It is assumed that claims of an unbiased antidepressant-like effect should be reserved for compounds that produce at least a 20% decrease in immobility time in the FST (Borsini and Meli, 1988) . Moreover, the observed slight antidepressant-like effects of S-(+ )-niguldipine do not necessarily relate to its properties as an α 1A -AR antagonist but could instead be associated with a blockade of voltage-dependent calcium channels. In particular, such effects are known to be produced by other calcium channel-blocking dihydropyridine derivatives, such as nimodipine and nifedipine (Czyrak et al., 1989) . However, it is noteworthy that neither of these calcium channel blockers induced any antidepressant-like effects in the FST after acute treatment (1 × ); instead these effects manifested only after subacute (3 × ) or chronic treatments (Czyrak et al., 1989) . Attempts to assess the effect of the chronic (over 14 days) administration of S-(+ )-niguldipine and the influence of chronic S-(+ )niguldipine administration on IMI treatment failed because of high lethality among the rats tested (data not shown).
The subacute administration of B8805-033 elicited clear antidepressant-like effects in rats treated with three doses of 5 or 10 mg/kg. To ensure that the effects observed in the FST were clearly related to the antidepressant properties of B8805-033, spontaneous locomotor activity (in the OFT) was assessed, and no differences between B8805-033 and control rats were observed. To eliminate possible contributions from the role of B8805-033 as a 5-HT 1A receptor agonist (Eltze et al., 2001a) , which is known to be responsible for antidepressant-like effects in the FST (Borsini and Meli, 1988; Lucki et al., 1994) , the experiment was repeated following the blockade of this serotonin receptor by its nonselective antagonist WAY100135 (Fletcher et al., 1993) . The results of these tests indicated that B8805-033-induced decreases in immobility times were attenuated or abolished by the concomitant administration of WAY100135, suggesting that the antidepressant-like effects elicited by B8805-033 are relatively unrelated to α 1A -ARs.
The adaptive changes in the noradrenergic system observed after antidepressant drug treatment are considered an important part of their action (Vetulani and Nalepa, 2000) . Our previous results indicated that α 1A -AR can be regarded an important target for antidepressant therapy (Nalepa et al., 2002 (Nalepa et al., , 2013 . Enhanced expression of α 1A -ARs after antidepressant treatment was observed only after therapies with a noradrenergic component to their action and this effect was nullified in animals that had a noradrenergic lesion before drug treatment (Nalepa et al., 2002; Kreiner et al., 2004 Kreiner et al., , 2011 . However, it was not possible to conclude from these results whether the observed changes in α 1A -AR are directly responsible for these antidepressant actions. Therefore, the effects of pharmacological blockade of α 1A -AR were studied, which still did not provide any further proof as the investigated compounds seem either not to be active in FST (i.e., S-(+ )-niguldipine) or their 
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The effects of the concomitant administration of WAY100135 and B8805-033 on antidepressant-like behavior in the forced swim test in rats. VEH, vehicle, control group; IMI, imipramine (3 × at 20 mg/kg); B88, B8805-033 (3 × at 10 mg/kg); WAY, WAY100135 (3 × at 0.1 or 0.3 mg/kg; administered 15 min before B8805-033). *P < 0.05 versus control group; **P < 0.01 versus control group; # P < 0.05 versus B8805-033; ## P < 0.01 versus B8805-033; n = 8-12.
action to not be mediated by α 1A -AR (i.e., B8805-033). Thus, because of the current dearth of selective α 1A -AR agonists, the question of whether this particular receptor subtype is involved in the mechanisms of antidepressant therapies remains unresolved. Nevertheless, it is worth emphasizing that, among all α 1 -AR subtypes, the α 1A -AR predominates in humans, possessing a number of splice variants (Coge et al., 1999) .
The physiological role of particular α 1 -AR subtypes in the brain is not fully understood, but considering the α 1A -ARmediated improvement of synaptic plasticity (Doze et al., 2011) that, according to existing hypothesis, is weakened in depression (Duman et al., 2000; Rajkowska et al., 1999) , impaired α 1A -AR signaling may be a factor determining the incidence of depressive disorders.
